Research graph
References from Combining an α v β 6 -Targeted 177 Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Current limitations and novel perspectives in pancreatic cancer treatment
10.3390/cancers14040985 · 2022 · External reference
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: single-center cohort study
10.4251/wjgo.v12.i2.182 · 2020 · External reference
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
10.1002/path.5320 · 2019 · External reference
10.1089/cbr.2014.1741
10.1089/cbr.2014.1741 · External reference
Peptide receptor radionuclide therapy—prospects for personalised treatment
10.1016/j.clon.2020.10.020 · 2021 · External reference
Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial
10.1200/jco.2018.78.5865 · 2018 · External reference
10.1038/s41571-022-00652-y
10.1038/s41571-022-00652-y · External reference
10.2967/jnumed.122.264749
10.2967/jnumed.122.264749 · External reference
DNA damage by radiopharmaceuticals and mechanisms of cellular repair
10.3390/pharmaceutics15122761 · 2023 · External reference
10.1016/j.molcel.2010.09.019
10.1016/j.molcel.2010.09.019 · External reference
10.1056/nejmoa1706450
10.1056/nejmoa1706450 · External reference
10.2174/1574892813666180305165256
10.2174/1574892813666180305165256 · External reference
10.1158/1078-0432.ccr-21-3577
10.1158/1078-0432.ccr-21-3577 · External reference
The role of olaparib in metastatic pancreatic cancer
2021 · External reference
10.1038/nature03443
10.1038/nature03443 · External reference
10.1038/nature03445
10.1038/nature03445 · External reference
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
10.1038/s41598-020-67199-9 · 2020 · External reference
Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer
10.1007/s00259-024-06844-1 · 2024 · External reference
10.7150/thno.15311
10.7150/thno.15311 · External reference
10.2967/jnumed.124.268902
10.2967/jnumed.124.268902 · External reference
LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)
10.1200/jco.2023.41.16_suppl.5005 · 2023 · External reference
Peptide receptor radionuclide therapy (PRRT): innovations and improvements
10.3390/cancers15112975 · 2023 · External reference
The ratio of total uptake volume on DOTATATE vs FDG PET is a predictive marker of treatment efficacy of Lu-177-DOTATATE in metastatic pheochromocytoma [abstract]
2023 · External reference
10.1056/nejmoa2105215
10.1056/nejmoa2105215 · External reference
10.1056/nejmoa1903387
10.1056/nejmoa1903387 · External reference
10.1038/s41416-021-01469-9
10.1038/s41416-021-01469-9 · External reference
10.1093/jnci/90.13.978
10.1093/jnci/90.13.978 · External reference
10.1093/jmcb/mjy072
10.1093/jmcb/mjy072 · External reference
